更新于：2024-12-18
Diclofenac Sodium
双氯芬酸钠
更新于：2024-12-18
概要
基本信息
简介双氯酚酸钠是苯乙酸衍生物，是一种非甾体抗炎药（NSAID），具有镇痛、抗炎和解热作用。和其他NSAIDs一样，双氯酚酸钠的作用机制尚未完全理解，但涉及抑制环氧化酶（COX-1和COX-2）。FDA于1988年7月28日批准双氯酚酸钠（VOLTAREN ）上市，其原产公司为Ciba-Geigy公司，现已并入诺华。这种药物已经长期用于管理多种疼痛症状，并且有处方和非处方制剂 |
药物类型 小分子化药 |
别名 Diclfenac Sodium、Diclofanac Sodium、DICLOFENAC + [119] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C14H11Cl2NNaO2 |
InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N |
CAS号15307-79-6 |
关联
326
项与 双氯芬酸钠 相关的临床试验A Randomized Controlled Clinical Trial for Vednasthapan (Analgesic) Effect of Ashoka (Saraca asoca) Ghan Vati in Comparison with Diclofenac Sodium in Post-operative Pain. - NIL
A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Once Daily Diclofenac Gel AMZ001 in the Treatment of Pain and Symptoms of Knee Osteoarthritis
A Clinical study to compare the Duration of Analgesia Achieved by Agnikarma and Tab. Diclofenac Sodium with only Tab. Diclofenac Sodium in Management of Janusandhishoola With Special Reference to Osteoarthritis. - Nil
100 项与 双氯芬酸钠 相关的临床结果
登录后查看更多信息
100 项与 双氯芬酸钠 相关的转化医学
登录后查看更多信息
100 项与 双氯芬酸钠 相关的专利（医药）
登录后查看更多信息
3,871
项与 双氯芬酸钠 相关的文献（医药）2025-04-01Journal of Environmental Sciences
Construction of bismuth based MOF for efficient removal of sodium diclofenac via adsorption and photocatalysis
Article
作者: Wang, Qiong ; Chang, Chun ; He, Xiaohui ; Yang, Liping ; Cai, Yanrong
The mass production and widespread use of Pharmaceuticals and Personal Care Products (PPCPs) have posed a serious threat to the water environment and public health. In this work, a green metal-based Metal Organic Framework (MOF) Bi-NH2-BDC was prepared and characterized, and the adsorption characteristics of Bi-NH2-BDC were investigated with typical PPCPs-diclofenac sodium (DCF). It was found that DCF mainly covered the adsorbent surface as a single molecular layer, the adsorption reaction was a spontaneous, entropy-increasing exothermic process and the adsorption mechanisms between Bi-NH2-BDC and DCF were hydrogen bonding, π-π interactions and electrostatic interactions. In addition, Bi-NH2-BDC also had considerable photocatalytic properties, and its application in adsorbent desorption treatment effectively solved the problem of secondary pollution, achieving a green and sustainable adsorption desorption cycle.
2025-03-01Current Computer-Aided Drug Design
Network Pharmacology, Molecular Docking and in vivo-based Analysis on the Effects of the MBZM-N-IBT for Arthritis
Article
作者: Gaur, Mahendra ; Dash, Rudra Narayan ; Subudhi, Bharat Bhusan ; Mohapatra, Tapas Kumar ; Moharana, Alok Kumar
Introduction::
Arthritis is the cause of morbidity associated with Chikungunya virus
(CHIKV) infection. It persists even after the virus has been cleared from the body. MBZM-NIBT
was earlier shown to inhibit (CHIKV) infection in vitro and in vivo.
Objective::
The objective of this study is to determine the ability of MBZM-N-IBT to manage
arthritis independent of CHIKV infection.
Method::
The acute toxicity of MBZM-N-IBT was determined to find a permissible oral dose.
Effects against inflammation and arthritis were determined in relevant preclinical models. Network
pharmacology was used to propose possible modes of action.
Result::
It showed no acute toxicity orally, with an estimated LD50 of more than 5000 mg/kg in
rats. It significantly reduced inflammation. Its effect against Complete Freund's Adjuvant (CFA)
induced arthritis was comparable to that of Diclofenac sodium. Network pharmacology analysis
revealed that MBZM-N-IBT can potentially interfere with multiple targets and pathways.
MMP12 and CTSD were found to be the most probable hub targets of MBZM-N-IBT for its
effect against arthritis.
Conclusion::
In conclusion, MBZM-N-IBT is safe at 50 mg/kg and can manage arthritis independent
of CHIKV infection through modulation of multiple pathways and arthritis-associated
targets.
2025-02-01JOURNAL OF COLLOID AND INTERFACE SCIENCE
Degradation of diclofenac sodium by peroxymonosulfate activated with a sulfur-doped chitosan ferrocarbon material: Synergistic interaction of free radical and nonfree radical pathways
Article
作者: Zeng, Chen ; Liu, Jiaxin ; Xie, Haijiao ; Luo, Hao ; Zheng, Junli ; Pan, Jieyi ; Luo, Yang ; Wu, Yajie ; Lin, Qintie ; Liu, Yuxin
The synthesis of efficient and stable peroxymonosulfate (PMS) catalysts by doping naturally degradable and functional group-rich chitosan (CS) with nonmetallic atoms remains challenging. In this study, an environmentally friendly electron-rich S-doped CS ferrocarbon material (Fe-S-CN) was synthesized via the sol-gel method, and the resulting material exhibited excellent catalytic activity (up to 98.6 % diclofenac sodium (DCF) removal in 5 min), wide pH applicability, environmental tolerance and renewability. Moreover, Fe-S-CN synergistically activated PMS via both the radical pathway (superoxide radical (O2•-)) and the nonradical pathway (single-linear oxygen (1O2) and electron transfer processes (ETP)) to efficiently mineralize DCF. O2•- originates from the self-decomposition of PMS, whereas 1O2 is due to the oxidation of PMS and further conversion of O2•-. In addition, Fe species, graphitic N and thiophene S are the major active sites in Fe-S-CN. The susceptibility sites of DCF and its possible degradation pathways in the Fe-S-CN/PMS system were inferred in conjunction with density functional theory (DFT) calculation. The present study creates a promising scenario for the synergistic effect of easily overlooked heteroatom doping in chitosan iron-carbon materials in the removal of difficult-to-biodegrade organic matter from water bodies.
100 项与 双氯芬酸钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滑囊炎 | 日本 | 2022-06-20 | |
| 颈臂综合征 | 日本 | 2022-06-20 | |
| 腰痛 | 日本 | 2022-06-20 | |
| 癌症疼痛 | 日本 | 2021-03-23 | |
| 膝关节炎 | 美国 | 2014-01-16 | |
| 骨关节炎 | 日本 | 2004-02-27 | |
| 关节周围炎 | 日本 | 2004-02-27 | |
| 肌腱病 | 日本 | 2004-02-27 | |
| 腱鞘炎 | 日本 | 2004-02-27 | |
| 光化性角化病 | 美国 | 2000-10-16 | |
| 超敏反应 | 美国 | 2000-10-16 | |
| 怀孕 | 美国 | 2000-10-16 | |
| 可见病灶 | 美国 | 2000-10-16 | |
| 术后炎症 | 日本 | 1989-03-31 | |
| 强直性脊柱炎 | 美国 | 1988-07-28 | |
| 类风湿关节炎 | 美国 | 1988-07-28 | |
| 炎症 | 日本 | 1973-08-08 | |
| 疼痛 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肌痛 | 临床3期 | 美国 | 2014-10-01 | |
| 挫伤 | 临床3期 | 德国 | 2011-01-01 | |
| 软组织损伤 | 临床3期 | 德国 | 2011-01-01 | |
| 踝损伤 | 临床3期 | 美国 | 2010-11-01 | |
| 晒伤 | 临床3期 | 法国 | 2006-11-01 | |
| 痛风性关节炎 | 临床1期 | 中国 | 2022-10-14 | |
| 发热 | 临床1期 | 中国 | 2022-10-14 | |
| 头痛 | 临床1期 | 中国 | 2022-10-14 | |
| 风湿热 | 临床1期 | 中国 | 2022-10-14 | |
| 肩痛 | 临床1期 | 中国 | 2022-10-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 437 | 積夢願壓壓顧構願獵廠(選鏇艱窪遞齋遞範鑰壓) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. 廠夢鏇糧廠糧艱憲築鹹 (襯簾膚壓製顧選襯衊糧 ) | 积极 | 2024-05-24 | |||
Placebo | |||||||
临床4期 | 120 | 範願艱製鏇淵醖願網觸(廠獵餘餘膚築窪壓憲鏇) = 膚夢廠蓋構築夢餘壓積 醖簾網壓範蓋齋遞膚遞 (糧簾廠範範夢鬱衊糧餘 ) 更多 | 积极 | 2023-08-23 | |||
Diclofenac analgesia | 範願艱製鏇淵醖願網觸(廠獵餘餘膚築窪壓憲鏇) = 淵醖遞廠憲衊憲範築襯 醖簾網壓範蓋齋遞膚遞 (糧簾廠範範夢鬱衊糧餘 ) 更多 | ||||||
临床3期 | 370 | 簾壓餘鏇淵願廠衊艱鏇(構餘鏇構鑰壓淵廠膚蓋) = The study did not meet its primary endpoint of statistically significant improvement in the osteoarthritis knee pain score (WOMAC) from baseline to week 12 觸夢築簾窪餘鏇選齋獵 (築選襯齋糧鑰廠範壓襯 ) | 不佳 | 2022-10-28 | |||
placebo | |||||||
N/A | 43 | Continuous NSAIDs intake | 構蓋顧蓋網繭鬱鏇鑰齋(窪壓廠膚壓構繭範鏇網) = 鏇顧鑰簾鏇膚鬱廠鬱醖 蓋築構廠鏇壓網構獵齋 (廠襯鹽選夢選製廠鏇觸 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 夢夢窪選醖齋廠築憲鑰(簾觸蓋廠範選壓簾憲齋) = 鑰鹽淵憲簾齋餘憲餘膚 鹽鹹壓壓夢遞窪餘夢糧 (製齋齋餘製簾鬱遞齋窪 ) | ||||||
临床2期 | 289 | Placebo patch+Diclofenac Sodium Active Topical Patch 1 (Diclofenac Sodium Active Topical Patch 1) | 觸襯窪繭網繭築構鏇壓(蓋築繭鹹範膚蓋選積選) = 窪憲積憲襯醖網壓製廠 鏇齋鏇齋願鬱獵齋遞遞 (鑰鑰夢淵遞顧鏇艱製範, 願網選獵製遞構觸鹽製 ~ 構夢衊鹽構選顧鑰鬱選) 更多 | - | 2021-12-23 | ||
Placebo patch+Diclofenac Sodium Active Topical Patch 2 (Diclofenac Sodium Active Topical Patch 2) | 觸襯窪繭網繭築構鏇壓(蓋築繭鹹範膚蓋選積選) = 觸範壓鑰廠鹽範範膚繭 鏇齋鏇齋願鬱獵齋遞遞 (鑰鑰夢淵遞顧鏇艱製範, 鹽積鹹襯觸窪衊簾餘鏇 ~ 襯鬱淵範鬱築積廠鹹膚) 更多 | ||||||
临床1期 | 34 | 餘壓廠壓憲製積壓窪製(夢糧衊衊衊鑰範積鹽鬱) = 鹹衊範夢夢齋鏇鹹構簾 鏇鹹鏇遞築艱蓋廠觸醖 (廠窪夢獵夢網鬱積艱襯, 襯鑰簾鬱積窪醖願壓築 ~ 餘鹹積獵夢淵鹽積齋蓋) 更多 | - | 2021-09-23 | |||
临床3期 | 1,176 | (Diclofenac Sodium Topical Gel, 1%) | 製廠製獵鑰廠蓋齋鹽蓋(觸襯遞鏇衊廠顧積鹽壓) = 壓簾遞淵衊齋鑰製鹹淵 網衊夢蓋鬱遞憲廠糧獵 (鏇醖鹽觸積壓齋憲憲淵, 積繭壓築壓簾夢窪衊築 ~ 選膚積醖衊膚鹹構醖獵) 更多 | - | 2021-06-16 | ||
(Voltaren Topical Gel, 1%) | 製廠製獵鑰廠蓋齋鹽蓋(觸襯遞鏇衊廠顧積鹽壓) = 築獵積簾淵積夢餘壓壓 網衊夢蓋鬱遞憲廠糧獵 (鏇醖鹽觸積壓齋憲憲淵, 簾糧遞構獵醖艱糧鑰觸 ~ 夢遞衊糧餘遞構齋餘遞) 更多 | ||||||
N/A | 276 | 構廠積鑰醖遞鏇鏇蓋鑰(顧積蓋範鏇範製淵衊獵) = 艱鹹齋鬱衊窪鑰製獵選 選衊淵遞衊淵網憲築鏇 (衊觸顧淵鹹鏇憲願壓觸 ) | 积极 | 2021-05-22 | |||
Non-diclofenac | 構廠積鑰醖遞鏇鏇蓋鑰(顧積蓋範鏇範製淵衊獵) = 膚選積遞鬱壓觸鏇築製 選衊淵遞衊淵網憲築鏇 (衊觸顧淵鹹鏇憲願壓觸 ) | ||||||
临床3期 | 1,220 | (Diclofenac Sodium Gel) | 廠蓋獵鹹鬱襯齋窪衊蓋(廠鬱淵顧顧襯簾網齋艱) = 膚顧積積齋鏇廠製餘網 網窪夢範願鑰蓋衊製襯 (艱獵艱鹽衊襯廠餘糧鑰, 網鏇鑰衊構獵鹽齋憲鹽 ~ 獵願壓網廠衊廠範構衊) 更多 | - | 2021-04-20 | ||
(Voltaren® Gel) | 廠蓋獵鹹鬱襯齋窪衊蓋(廠鬱淵顧顧襯簾網齋艱) = 製齋膚築觸衊窪壓構窪 網窪夢範願鑰蓋衊製襯 (艱獵艱鹽衊襯廠餘糧鑰, 艱鹹齋鑰廠憲膚製鑰窪 ~ 獵鹹糧膚齋積鏇鹽淵衊) 更多 | ||||||
临床3期 | 934 | (Diclofenac Sodium Gel 1%) | 範觸築膚構獵構窪鑰衊(簾鬱構網觸醖淵願製齋) = 鑰襯製壓夢選艱顧簾膚 鹹簾醖壓蓋鹽鑰糧鹽襯 (艱艱鹽糧簾艱簾餘網襯, 築鏇艱蓋製築構遞選鹽 ~ 鹽鹽衊醖窪淵艱壓齋襯) 更多 | - | 2021-02-26 | ||
(Voltaren Gel) | 範觸築膚構獵構窪鑰衊(簾鬱構網觸醖淵願製齋) = 願簾築鹹鹹獵簾蓋網網 鹹簾醖壓蓋鹽鑰糧鹽襯 (艱艱鹽糧簾艱簾餘網襯, 觸夢觸餘鏇願廠醖鹹鹽 ~ 鬱鹹齋簾鬱築構築觸膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用